Inventiva (NASDAQ:IVA) Trading Down 7% – Here’s Why

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares fell 7% during mid-day trading on Wednesday . The stock traded as low as $4.36 and last traded at $4.3440. 1,059,394 shares traded hands during mid-day trading, an increase of 57% from the average session volume of 676,366 shares. The stock had previously closed at $4.67.

Analyst Upgrades and Downgrades

IVA has been the subject of a number of recent research reports. Cantor Fitzgerald initiated coverage on shares of Inventiva in a report on Friday, July 17th. They issued an “overweight” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Inventiva currently has a consensus rating of “Buy” and an average target price of $15.38.

Inventiva Price Performance

The stock has a 50-day moving average price of $4.57 and a two-hundred day moving average price of $4.96.

Institutional Investors Weigh In On Inventiva

Large investors have recently modified their holdings of the business. Paradigm Biocapital Advisors LP purchased a new position in shares of Inventiva in the 4th quarter valued at approximately $18,600,000. ADAR1 Capital Management LLC purchased a new stake in Inventiva during the 4th quarter worth approximately $12,601,000. UBS Group AG grew its position in Inventiva by 28,881.6% during the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after purchasing an additional 2,634,580 shares during the last quarter. SymBiosis Capital Partners LLC acquired a new position in Inventiva during the 4th quarter valued at approximately $12,090,000. Finally, Millennium Management LLC increased its stake in Inventiva by 2,267.7% during the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock valued at $12,334,000 after purchasing an additional 2,540,540 shares in the last quarter. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.